• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Medivo Rebrands as Prognos to Leverage AI for Earlier Disease Detection

by Jasmine Pennic 01/09/2017 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

 

Medivo Rebrands as Prognos to Leverage AI for Earlier Disease Detection

After six years of research and development exploring the potential of clinical diagnostic assets, Medivo has rebranded as Prognos. The new artificial intelligence-focused company mission is to help payer, life sciences and diagnostics organization track and predict disease earlier through advanced analytics and artificial intelligence techniques. The company is supported by a $23M investment from Safeguard Scientifics, Inc. and Merck Global Health Innovation Fund (GHIF).

Prognos has already partnered with Cigna, Biogen and Quest Diagnostics by offering access to its Prognos Registry, the largest source of clinical diagnostics information in over 30 disease areas, with over 5B medical records for 100M patients. Prognos has 500 extensive proprietary and learning clinical algorithms to enable earlier patient identification for enhanced treatment decision-making, risk management and quality improvement. Cigna is already using Prognos analytics to improve health engagement among its Individual and Family Plan customers.

“Prognos’ analytics help us identify customers with chronic conditions such as diabetes, rheumatoid arthritis, and hepatitis C, so that we can engage them early and support them with health management options,” said Brian Evanko, president of Cigna’s Individual and Family Plans segment. “This helps drive better health outcomes for our customers, resulting in improved health care quality and a better customer experience.”

Key benefits of that AI platform include:

·       For Life Sciences, Prognos solutions help brands dependent on biomarkers educate providers on therapy options for newly-diagnosed patients – before treatment decisions are made. Unlike Rx or claims data, clinical diagnostics data comes before treatment decisions have been made; lab tests influence 70% of medical decisions and 100% of treatment decisions for some conditions.

·       For payers, Prognos solutions enable engagement with providers earlier in the patient treatment process to improve quality of care. This also reduces avoidable care costs, especially for patients with chronic conditions and comorbidities. Clinical diagnostic analytics can improve quality, HEDIS outcomes and Star ratings.

·       For patients, Prognos AI solutions mean better treatment decision-making and outcomes.

“The launch of Prognos elevates our ability to leverage the largest aggregated database of lab results in the U.S. and deliver actionable clinical insights to the medical community,” said Sundeep Bhan, Prognos Co-Founder and CEO in a statement.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Artificial Intelligence in Healthcare, Clinical Data Analytics, Prognos

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |